CoChat

A Risk-Benefit Assessment of the Levonorgestrel-Releasing Intrauterine System

Sturridge, Frances, Guillebaud, John · 1996 · Drug Safety

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Abstract

The levonorgestrel-releasing intrauterine system (LNG-IUS), has been developed by Leiras Pharmaceuticals, Turku, Finland. It is a new systemic hormonal contraceptive that releases levonorgestrel 20 micrograms every 24 hours. The device provides fertility control comparable with that of female sterilisation, complete reversibility and convenience, and has an excellent tolerability record. The low dosage of levonorgestrel released by its unique delivery system ensures minimal hormone-related systemic adverse effects, which tend to be in the category of 'nuisance' rather than hazardous, and gradually diminish after the first few months of use. In some respects, the contraceptive characteristics of the LNG-IUS have over-shadowed a substantial range of noncontraceptive beneficial effects that are rarely seen with inert or copper-releasing intrauterine contraceptive devices (IUDs), and have important and positive gynaecological and public health implications. This applies particularly to the profound reduction in duration and quantity of menstrual bleeding, and alleviation of dysmenorrhoea, which are associated with the use of the device. Recent studies have shown that the LNG-IUS is effective in preventing endometrial proliferation associated with oral or transdermal estradiol therapy, and in inducing regression of endometrial hyperplasia. Further research is required to determine whether it has a role in regulating the growth of uterine fibroids, and preventing pelvic inflammator…

Overview

Integrity signals

Registry

Crossref · 10.2165/00002018-199615060-00006

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Cited by

See all 69

Metadata

Authors
Sturridge, F., & Guillebaud, J.
Venue
Drug Safety
Published
1996-12
Volume
15
Issue
6
Pages
430-440
ISSN
0114-5916 (ISSN-L)
OpenAlex
W2144897291
Cited by
69
References
61
Citations by year
2026: 1 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
0.49
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Social Sciences › Political Science and International Relations › International Human Rights and Reproductive Law
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
levonorgestrel-releasing intrauterine system, hormonal intrauterine device, contraceptive safety, non-contraceptive benefits, menstrual bleeding reduction, dysmenorrhea, endometrial hyperplasia, endometrial proliferation, uterine fibroids, pelvic inflammatory disease, ovarian cysts, ovarian function, patient counseling
MeSH terms
Delayed-Action Preparations, Female, Humans, Intrauterine Devices, Medicated, Levonorgestrel, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Risk-Benefit Assessment of the Levonorgestrel-Releasing Intrauterine System. https://app.cochat.ai/papers/10.2165/00002018-199615060-00006
The paper
Sturridge, F., & Guillebaud, J. (1996). A Risk-Benefit Assessment of the Levonorgestrel-Releasing Intrauterine System. Drug Safety. https://doi.org/10.2165/00002018-199615060-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.